TPX-0005 is primarily utilized in the field of oncology as a potent and selective inhibitor of ALK (Anaplastic Lymphoma Kinase), ROS1 (ROS Proto-Oncogene 1), and TRK (Tropomyosin Receptor Kinase) fusion proteins. Its application is critical in targeting and treating various types of cancers, particularly non-small cell lung cancer (NSCLC) and other solid tumors that harbor these genetic alterations. By inhibiting these kinases, TPX-0005 disrupts the signaling pathways that drive tumor growth and survival, offering a therapeutic option for patients with resistant or refractory cancers. It is also being investigated for its potential to overcome resistance mechanisms that develop in response to earlier-generation kinase inhibitors, making it a promising candidate for precision medicine approaches in cancer therapy.